- cafead Nov 22, 2021 at 10:22: PM
via Some of Amgen’s key businesses are drawing concerns as competition looms.
Amgen’s 2022 sales could be about $26.3 billion, or $700 million lower than industry watchers’ current expectations, Mizuho analyst Salim Syed warned in a Monday note to investors.
The company’s biosimilars franchise, PCSK9 cholesterol drug Repatha and inflammatory disease therapy Otezla could become its weak points, Syed said.
article source
Amgen’s 2022 sales could be about $26.3 billion, or $700 million lower than industry watchers’ current expectations, Mizuho analyst Salim Syed warned in a Monday note to investors.
The company’s biosimilars franchise, PCSK9 cholesterol drug Repatha and inflammatory disease therapy Otezla could become its weak points, Syed said.
article source